Synaffix Inks $586 Million Deal with MacroGenics to Enable Next Generation ADCs

Published on: 

MacroGenics will use Synaffix’s technology to investigate next-generation ADCs.

Synaffix, a biotechnology company, announced on Feb. 3, 2022 that it has entered into a technology agreement with MacroGenics, a company interested in oncology therapies. Under the terms of the agreement, MacroGenics will pay up to $586 million to use various Synaffix platforms to investigate antibody-drug conjugates (ADCs).

In addition to its own proprietary antibody and bispecific dual-affinity re-targeting antibody platforms, MacroGenics will now also have access to Synaffix’s:

  • GlycoConnect antibody conjunction technology
  • HydroSpace polar space technology
  • Select toxSYN linker-payloads: SYNtecan E, SYNeamicin D, and SYNeamicin G.

“We are delighted to be working with Synaffix to produce next generation ADCs with potentially superior therapeutic properties,” said Ezio Bonvini, chief scientific officer of MacroGenics, in a company press release. “The ability to obtain all essential ADC technologies from Synaffix, and easily and rapidly combine those with our antibody-based molecules, will enable us to expand our existing portfolio of ADC product candidates and further strengthen our position in the growing ADC field.”

“The collaboration with MacroGenics is an important milestone for Synaffix as our ADC technology will be deployed for the generation of both monospecific and bispecific ADCs,” said Peter van de Sande, CEO of Synaffix, in the press release. “We are pleased to further expand the use of our technology with another leading biotech company that has deep product development capabilities and a long-term commitment to delivering novel therapies for the treatment of cancer.”

Source: Synaffix